CoChat

Pharmacotherapy for gestational diabetes

Patti, Angelo Maria, Giglio, Rosaria Vincenza, Pafili, Kalliopi, Rizzo, Manfredi, Papanas, Nikolaos · 2018 · Expert Opinion on Pharmacotherapy

The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Gestational diabetes mellitus (GDM) represents impaired carbohydrate metabolism during pregnancy and is characterized by progressive insulin resistance and compensatory hyperinsulinaemia. If inadequately treated, it may lead to fetal macrosomia and other adverse outcomes. AREAS COVERED: In this review, the authors summarize the current evidence from studies on the use of insulin and other agents for the treatment of women with GDM. EXPERT OPINION: Lifestyle management is of paramount importance for the treatment of GDM. In pharmacotherapy, insulin remains the long-established mainstay of treatment. NPH (Neutral Protamine Hagedorn) and soluble human insulin have long been established for use, but favorable experience has now also accumulated with the newer insulins (aspart, lispro, detemir). Alternatively, metformin and glyburide have been used in GDM, but they have never gained wide acceptance. Nutritional supplements based on micronutrients and bioactives (probiotics and myoinositol) have shown promising results as well. Further experience with incretin agents (DPP-4 inhibitors and GLP-1 receptor agonists) is awaited.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2018.1509955

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 110 references

Research works printed but not linked: 7

  1. O’Sullivan JB, 1966, Obstet Gynecol, 27, 683
  2. Jenum AK, 2013, Food Nutr Res, 57
  3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2013, Can J Diabetes, 37, S168
  4. Berneis K, 2004, Swiss Med Wkly, 134, 720
  5. Zárate A, 2000, Ginecol Obstet Mex, 68, 42
  6. de-Regil LM, 2016, Cochrane Database Syst Rev, 1, CD008873
  7. Food and Drug Administration, HHS [Corporate authors], 2014, Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling

Cited by

See all 19

Metadata

Authors
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N.
Affiliations
  • University of Palermo (IT)
  • Democritus University of Thrace (GR)
  • Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece
Venue
Expert Opinion on Pharmacotherapy
Published
2018-08-23
Volume
19
Issue
13
Pages
1407-1414
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2888321467
Cited by
19
References
110
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 2
FWCI
0.36
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Funders
not funded or sponsored
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
gestational diabetes mellitus, insulin therapy, NPH insulin, soluble insulin, insulin aspart, insulin lispro, insulin detemir, metformin, glibenclamide, lifestyle management, micronutrient supplementation, probiotics, myo-inositol, DPP-4 inhibitors, GLP-1 receptor agonists, insulin resistance, macrosomia
MeSH terms
Female, Humans, Hypoglycemic Agents, Insulin, Pregnancy, Pregnancy Complications, Diabetes, Gestational, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacotherapy for gestational diabetes. https://app.cochat.ai/papers/10.1080/14656566.2018.1509955
The paper
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N. (2018). Pharmacotherapy for gestational diabetes. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2018.1509955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.